Description

SUCRAFIL 1GM (1X10)

Indications

SUCRAFIL 1GM is primarily indicated for the management of peptic ulcers, including gastric and duodenal ulcers. It is also used in the treatment of gastroesophageal reflux disease (GERD) and as a protective agent against mucosal injury caused by nonsteroidal anti-inflammatory drugs (NSAIDs). SUCRAFIL acts by forming a protective barrier over the ulcer site, thereby promoting healing and alleviating symptoms associated with these gastrointestinal disorders.

Mechanism of Action

The active ingredient in SUCRAFIL is sucralfate, which is a complex of sucrose sulfate and aluminum hydroxide. Upon contact with gastric acid, sucralfate undergoes a transformation to form a viscous gel that adheres to the ulcerated tissue. This gel acts as a physical barrier, protecting the ulcer from further injury by gastric acids, bile salts, and pepsin. Additionally, sucralfate may stimulate the production of prostaglandins and mucosal bicarbonate, contributing to enhanced mucosal defense and promoting healing.

Pharmacological Properties

SUCRAFIL exhibits unique pharmacokinetic properties. It is minimally absorbed in the gastrointestinal tract, with less than 3% of the administered dose entering systemic circulation. This low systemic absorption minimizes the potential for systemic side effects. The drug’s action is localized primarily in the gastrointestinal tract, where it exerts its protective effects. The onset of action is generally observed within 1 to 2 hours after administration, and its effects can last for up to 6 hours, making it suitable for multiple daily dosing.

Contraindications

SUCRAFIL is contraindicated in patients with known hypersensitivity to sucralfate or any of its components. It should also be avoided in individuals with severe renal impairment due to the potential accumulation of aluminum, which can lead to toxicity. Patients with a history of gastrointestinal obstruction or those who are at risk for bowel obstruction should not use this medication without medical supervision.

Side Effects

While SUCRAFIL is generally well-tolerated, some patients may experience side effects. Common side effects include constipation, dry mouth, and gastrointestinal discomfort. Rarely, allergic reactions may occur, presenting as rash, itching, or swelling. In patients with renal impairment, there is a risk of aluminum toxicity, which can manifest as encephalopathy or bone disease. It is important for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of SUCRAFIL for adults typically involves taking 1 gram (1 tablet) four times daily, preferably on an empty stomach, one hour before meals and at bedtime. For the treatment of duodenal ulcers, the usual duration of therapy is 4 to 8 weeks, depending on the severity of the condition and the patient’s response to treatment. It is essential to follow the prescribing physician’s instructions regarding dosage adjustments and duration of therapy, particularly in special populations such as the elderly or those with renal impairment.

Interactions

SUCRAFIL may interact with other medications, potentially affecting their absorption and efficacy. It is known to bind to certain drugs, including antacids, digoxin, phenytoin, and warfarin, which can decrease their bioavailability. Therefore, it is advisable to separate the administration of SUCRAFIL from other medications by at least 2 hours to minimize the risk of interactions. Patients should inform their healthcare provider about all medications they are currently taking, including over-the-counter drugs and supplements.

Precautions

Before initiating treatment with SUCRAFIL, it is crucial to conduct a thorough assessment of the patient’s medical history, particularly regarding renal function and any history of gastrointestinal disorders. Caution should be exercised in patients with diabetes, as the sucrose component may affect blood glucose levels. Regular monitoring of renal function is recommended for patients on long-term therapy, especially those with pre-existing renal conditions. Pregnant and breastfeeding women should consult their healthcare provider before using SUCRAFIL, as the safety of sucralfate in these populations has not been fully established.

Clinical Studies

Clinical studies have demonstrated the efficacy of SUCRAFIL in promoting ulcer healing and providing symptomatic relief in patients with peptic ulcers. A randomized controlled trial published in the Journal of Gastroenterology found that sucralfate was effective in healing duodenal ulcers within 4 to 8 weeks of treatment. Another study indicated that sucralfate significantly reduced the incidence of NSAID-induced gastric mucosal injury when used as a prophylactic agent. These findings support the use of SUCRAFIL as a valuable therapeutic option in managing gastrointestinal disorders.

Conclusion

SUCRAFIL 1GM is a well-established medication for the treatment of peptic ulcers and gastroesophageal reflux disease. Its unique mechanism of action, combined with its favorable pharmacological properties, makes it an effective choice for patients requiring mucosal protection. While generally safe, it is essential for patients to be aware of potential side effects and interactions with other medications. As with any medication, SUCRAFIL should be used under the guidance of a healthcare professional to ensure optimal therapeutic outcomes.